SPECT/CT Prospective Double-Scanning Study

July 21, 2026 updated by: GE Healthcare

Demonstration of the StarGuide GX SPECT/CT System

The goal of this study is to collect image data for StarGuide GX SPECT/CT System in a clinical setting. The StarGuide GX scan will be compared to the participant's clinically indicated SPECT/CT scanner. Participants will be adult patients scheduled to undergo a clinically indicated SPECT/CT.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Israel
      • Haifa, Israel, 3109601
        • Rambam Health Care Campus
        • Contact:
        • Principal Investigator:
          • Zohar Keidar, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Participants who have a clinically indicated SPECT/CT examination according to current clinical practice standards and according to the data required for the study will be enrolled in this study.

Description

Inclusion Criteria:

  • Adult, who is at least 18 years of age, on day of consent.
  • Must have a clinical indicated SPECT/CT exam scheduled according to current clinical practice standards; AND
  • Able and willing to provide informed consent for participation in this study.

Exclusion Criteria:

  • Who, per the site's SOPs, has any condition that would prevent the clinically indicated SPECT/CT from proceeding (i.e., pregnancy, breastfeeding, renal impairment, etc.);
  • Who were previously enrolled in this study;
  • Who need urgent or emergent care;
  • Who have any conditions that, in the opinion of the PI or designee, would interfere with the evaluation of the results, constitute a health hazard for the participant;
  • Unwilling to have GEHC personnel present during scans; OR
  • Unable to tolerate the exam.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Single Group Study
Adult patients scheduled to undergo a clinically indicated SPECT/CT
Device: StarGuide GX SPECT/CT Scan
Participants will undergo two SPECT/CT scans and will be randomized to determine whether imaging with the StarGuide GX scanner or the commercially released reference scanner is performed first. The second scan will begin within one hour of completion of the first scan. No additional tracer will be administered prior to the second imaging session, as both scans will utilize the initially administered dose. Following completion of both scans, participants will be asked to complete a brief questionnaire.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of StarGuide GX Data Files Collected
Time Frame: Through study completion, an average of 1 year
Through study completion, an average of 1 year

Secondary Outcome Measures

Outcome Measure
Time Frame
Number of reference data files
Time Frame: Through study completion, an average of 1 year
Through study completion, an average of 1 year
Number of Participant Questionnaires Collected
Time Frame: Through study completion, an average of 1 year
Through study completion, an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

GE Healthcare

Collaborators

Rambam Health Care Campus

Investigators

  • Study Director: Brian Thomsen, GE Healthcare

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 1, 2026

Primary Completion (Estimated)

February 1, 2027

Study Completion (Estimated)

February 1, 2027

Study Registration Dates

First Submitted

July 21, 2026

First Submitted That Met QC Criteria

July 21, 2026

First Posted (Actual)

July 24, 2026

Study Record Updates

Last Update Posted (Actual)

July 24, 2026

Last Update Submitted That Met QC Criteria

July 21, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • SA-000219

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on SPECT-CT

Clinical Trials on StarGuide GX SPECT/CT Scan

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe